U.S. markets close in 3 hours 58 minutes
  • S&P 500

    3,837.37
    +17.65 (+0.46%)
     
  • Dow 30

    31,421.82
    +151.73 (+0.49%)
     
  • Nasdaq

    13,016.21
    +18.46 (+0.14%)
     
  • Russell 2000

    2,198.92
    -8.88 (-0.40%)
     
  • Crude Oil

    64.45
    +3.17 (+5.17%)
     
  • Gold

    1,714.20
    -1.60 (-0.09%)
     
  • Silver

    26.23
    -0.16 (-0.59%)
     
  • EUR/USD

    1.2048
    -0.0019 (-0.16%)
     
  • 10-Yr Bond

    1.4770
    +0.0070 (+0.48%)
     
  • GBP/USD

    1.3998
    +0.0045 (+0.32%)
     
  • USD/JPY

    107.6050
    +0.6030 (+0.56%)
     
  • BTC-USD

    49,724.41
    -1,044.79 (-2.06%)
     
  • CMC Crypto 200

    997.56
    +10.35 (+1.05%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Xenon Pharmaceuticals Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:

  • Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on Monday, November 16, 2020

  • Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 pm ET

  • Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 9:40 am ET (2:40 pm GMT)

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com